Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

IAG – Recovery Play

Posted on | by Leon Hinde

We add IAG to our “high risk” recovery basket, which also includes CIM & A2M.

We expect IAG to see improved earnings into FY22 & FY23. It’s likely we’re nearing the inflection point, where investors begin pricing in the anticipated recovery.

Buy IAG with stops below $4.60

Ampol – Technical Review

Posted on | by Leon Hinde

Ampol has reported its financials for the 12 months ending 31 December 2020, with full year earnings of $401 million. Earnings were down from $607 million in the year prior.

1Q21 EBIT was A$150mn, but included an A$18mn FX gain.